Kadimastem
Ness Ziona
About Kadimastem
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin secreting beta cells as well as a range of neural cells, including Oligodendrocytes and Astrocytes. Based on its differentiation technologies, the company advances two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells for the diabetes program and astrocytes are differentiated into beta cells for the ALS program, with the goal of implanting them into patients, and affecting diseases progression. The company’s technology is designed to screen compounds automatically and quantify the readouts using a cell-based High Content Screening (HCS) system. Kadimastem partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells. It produces a number of human cell and tissue systems that constitute screening platforms to search for agonists or antagonists of specific biological processes, with the aim of developing safe drugs. Kadimastem is based in Nes Ziona, Israel.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $22.1M
- Funding stage: M&A
- Last round: Grant (Jul 2025)
- Ticker: tlv:KDST
- Website: kadimastem.com
- Phone: 97297289100698
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kadimastem-173314 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.